Marcela Maus: Expanding our clinical research around CAR-T therapy

Marcela Maus, Director of Cellular Immunotherapy, MGH Cancer Center Associate Professor at Harvard Medical School, posted on LinkedIn:

“As you’ve likely seen from my team, we are entering the summer intent on expanding our clinical research around CAR-T therapy, which resulted in “dramatic and rapid” regression of glioblastoma in our Phase 1 study. No cancer center can make research-based advances like this without the support of public and private sector partners.

That’s why I’m eager to meet this week with Members of Congress to reinforce the significant impact NIH has on advancing science. With the help of NIH research grants over the course of many years, we are exploring new frontiers in treatment using CAR-T, CRISPR and other therapeutics. It’s clear that sustained support is necessary to discover new, more effective treatments for patients.”

View the article attached to the post.
Source: Marcela Maus/LinkedIn